171 related articles for article (PubMed ID: 16804392)
1. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R; Barish CF; Riff D; Pruitt R; Chey WY; Farraye FA; Shafran I; Katz S; Krone CL; Vander Vliet M; Stevens C; Sherman ML; Jacobson E; Bleday R
Inflamm Bowel Dis; 2006 Jul; 12(7):558-65. PubMed ID: 16804392
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
5. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
Wada Y; Lu R; Zhou D; Chu J; Przewloka T; Zhang S; Li L; Wu Y; Qin J; Balasubramanyam V; Barsoum J; Ono M
Blood; 2007 Feb; 109(3):1156-64. PubMed ID: 17053051
[TBL] [Abstract][Full Text] [Related]
6. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich A
IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
[TBL] [Abstract][Full Text] [Related]
8. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
9. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
[TBL] [Abstract][Full Text] [Related]
10. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
12. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
[TBL] [Abstract][Full Text] [Related]
13. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics for induction and maintenance of remission in Crohn's disease.
Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
Sands BE; Winston BD; Salzberg B; Safdi M; Barish C; Wruble L; Wilkins R; Shapiro M; Schwertschlag US;
Aliment Pharmacol Ther; 2002 Mar; 16(3):399-406. PubMed ID: 11876692
[TBL] [Abstract][Full Text] [Related]
18. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
[TBL] [Abstract][Full Text] [Related]
20. Budesonide for maintenance of remission in Crohn's disease.
Benchimol EI; Seow CH; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2009 Jan; (1):CD002913. PubMed ID: 19160212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]